ADVERTISEMENT

Anti Malaria Drug Hydrooxychloroquine Now a Schedule H1 Drug

Anti Malaria Drug Hydrooxychloroquine Now a Schedule H1 Drug

Published
Fit
1 min read
Anti Malaria Drug Hydrooxychloroquine Now a Schedule H1 Drug

Anti malaria drug Hydrooxychloroquine has now been declared a Schedule H1 Drug by Ministry of Health and Family Welfare after reports of hoarding coming from across the country. This comes after Indian Council fo Medical Research or ICMR approved hydrooxychloroquine as a prophylactic for specific people including healthcare workers and family members in immediate contact of a COVID-19 person.

A Schedule H1 drug means it can only be sold on a prescription by a qualified medical professional. It also means that its box will have a warning label of only prescription sale and against self-medication, and chemists would need to maintain records of sale.

ICMR's approval for the drug has come under question as most studies on the efficacy of the drug are small. While promising, clinical research of the drug is on going in multiple places, with some studies indicating it could turn toxic. There was also a recent death reported in the US after a man over dosed on the drug. This came after the US President Donald Trump over sold the drug as the most promising.

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

ADVERTISEMENT
Speaking truth to power requires allies like you.
Become a Quint Insider
25
100
200

or more

PREMIUM

3 months
12 months
12 months
Check Insider Benefits
ADVERTISEMENT
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
ADVERTISEMENT
×
×